Supplementary
: E-cadherin cell membrane localization is aberrant in human prostate cancer cell lines that do not express α-catenin. A. Representative immunofluorescent images of E-cadherin (green) and DAPI (blue) stained PC-3, PC-3M, LNCaP, and LNCaP C4-2B cell lines cultured on glass chamber slides. B. Representative immunofluorescent images of co-localization (yellow) of E-cadherin (green) and α-catenin (red) in PC-3, PC-3M, LNCaP, and LNCaP C4-2B cell lines cultured on glass chamber slides (DAPI [blue] ). Images were obtained at 60x magnification, scale bars = 15 μm (n=3). C. RT-qPCR analysis of mRNA; data presented as relative expression (mean ± SEM) compared to pooled reference RNA (n=3). D. Immunoblot analysis of protein expression; presented as quantitative densitometric data (mean ± SEM) relative to an appropriate positive control cell line and as a representative immunoblot, shown as a cropped gel image (n=3). E. Flow cytometry analysis; presented as relative fluorescence intensity (expression; mean ± SEM) compared to an appropriate positive control cell line (n=3). Figure S3 : CTC recovery using the CellSearch® system is reduced in human prostate cancer cells with a mesenchymal phenotype. Prostate cancer cells were counted by hemocytometer and spiked at a concentration of 1,000 tumor cells/50μl of whole mouse blood. 50μl of mouse blood was subsequently processed using 1 of 2 mouse-adapted protocols and CTC recovery was measured as a percentage recovery of the number of spiked cells. A. CTC recovery using the EMT-dependent assay is significantly lower in cells with a more mesenchymal and metastatic phenotype. B. CTC recovery using the EMT semi-independent assay is lower relative to the EMT dependent assay. However, equivalent recovery is observed across all 4 cell lines regardless of EMT phenotype. C. Reduced recovery observed when using the EMT semi-independent assay was further investigated and determined to be as a result of extra processing steps required in this protocol. Data are presented as the mean ± SEM (n=3). Analysis of differences in CTC recovery using the 2 assays was performed using 1-way ANOVA with Tukey's post-test for multiple comparisons. * = significantly different (p ≤ 0.05). Figure S5: The mesenchymal PC-3M and PC-3 cell lines exhibit a greater incidence of lymph node metastases and mean lymph node metastatic burden. A. Incidence of lymph node metastasis in mice injected with PC-3M, PC-3, LNCaP C4-2B, and LNCaP prostate cancer cell lines based on microscopic histological examination of formalin fixed, H&E stained tissue following orthotopic injection. Data are presented as the percentage of mice per cell line per timepoint with detectable lymph node metastases (n=7-39 mice/group). B. Quantitative analysis of tumor burden (mean % of lymph nodes occupied by tumor) following orthotopic injection of prostate cancer cell lines. Data are presented as the mean ± SEM (n=7-39 mice/group). Differences in the incidence of lymph node metastasis were assessed using Fisher's Exact Test. Differences in metastatic burden to the lymph nodes were assessed by Wilcoxon Score followed by a Kruskal-Wallis test. * = significantly different (p≤0.05). C. Representative H&E and IHC (E-cadherin and N-cadherin) images of lymph node metastases for each investigated cell line. Histological sections are presented at 40x magnification. Arrowheads on H&E images indicate regions of tumor within the given tissue. Scale bars=50 μm. Sequence specific primers were designed based on gene sequence information from the National Center for Biotechnology Information (NCBI; Bethesda, MD). 

